Sailing towards early detection: Aussie company charts new course for breast cancer screening
Sailing towards early detection: Aussie company charts new course for breast cancer screening
About this video
Jane Shaw, the Executive Chair of BCAL Diagnostics (BDX), discusses the opening of their new clinical development laboratory and the progress of their lipidomic signature test for breast cancer detection. The laboratory will run tests using a blood sample to identify the presence of breast cancer based on the lipidomic signature. The company has been conducting trials for the past 12 years and has reached a level of scientific validation that clinicians are satisfied with. The test will be used as a diagnostic tool alongside mammography and will primarily serve as a monitoring tool for women who have had breast cancer.
BCAL Diagnostics is actively seeking samples from women to validate and advance the science further. It is still looking for more blood samples from a wide cross section of ethnicity, age and health status, to participate in the ongoing development of its blood screening innovation. You can register your interest online at www.bcaldiagnostics.com.
The company has engaged shareholders who have a personal connection to breast cancer and is working closely with clinicians, doctors, and advocacy groups. The technology used in the test is novel and unique, focusing on lipidomics, which has generated significant interest. The goal is to improve early detection rates and survivability of breast cancer, reducing the number of deaths caused by the disease.